Key result
Lifestyle, drug, and device therapies modulate hypertension-related sympathetic overdrive despite assessment limitations.
Why the study?
The study aimed to examine the effects of nonpharmacological, pharmacological, and device-based treatments on hypertension-related sympathetic overactivity by analyzing published studies assessing sympathetic activity.
Do nonpharmacological, pharmacological, and device-based interventions reduce hypertension-related sympathetic overdrive?
Do nonpharmacological, pharmacological, and device-based interventions reduce hypertension-related sympathetic overdrive?
This review summarizes the effects of various lifestyle, pharmacological, and device-based interventions on modulating sympathetic overactivity in hypertension.
Limits firm recommendations for sympathetic-targeted therapies in hypertension; leaves open need for standardized trials to guide practice.
The present study aims to examine the effects of nonpharmacological, pharmacological and devices-based treatment on hypertension-related sympathetic overactivity. This will be done by analyzing the results of different published studies, in which sympathetic activity has been assessed via indirect or direct techniques. After examining the rationale for sympathomodulatory interventions in antihypertensive treatment, the study will discuss the methodological intrinsic limitations of the studies aimed at assessing different therapeutic interventions. The core of the study will be then focused on the effects of nonpharmacological (dietary restriction of sodium intake, physical exercise training, weight reduction), pharmacological (monotherapy, combination drug treatment, new drugs such as sodium glucose co-transport protein-2 inhibitors and angiotensin receptor neprilysin inhibitors), as well as devices-based interventions (renal sympathetic nerves ablation and carotid baroreceptor activation therapy) on the hypertension-related sympathetic overdrive. Finally, the areas worthy of future research as well as the debated issues in the field will be highlighted.
No takes yet. Share an insight, caveat, or question.
Guıdo Grassı (2023) conducted a review in hypertension-related sympathetic overactivity. nonpharmacological, pharmacological, and device-based treatments was evaluated on hypertension-related sympathetic overdrive. Nonpharmacological, pharmacological, and device-based treatments modulate hypertension-related sympathetic overactivity, though methodological limitations exist in assessing these interventions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: